Clinical Trial Update: Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer [Phase 1]

View source ↗

Summary

This update reports completion of a Phase Ib dose-escalation study evaluating taselisib (GDC-0032) in combination with anti-HER2 therapies in adults with advanc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Taselisib (GDC-0032)

Snippet

Sponsor: Otto Metzger, MD | Conditions: Metastatic Breast Cancer, Recurrent Breast Cancer | Phase 1 | Status: COMPLETED